Prodeon Medical Launched Temporary Prostate Implant
The device offers a non-permanent alternative for treating benign prostatic hyperplasia, shifting current surgical standards.
Updated on Oct. 14, 2026 in Healthcare
Live Poll
Would you prefer a removable medical implant over a permanent one for a chronic condition?
Prodeon Medical initiated a controlled commercial release of the Urocross Expander System, completing its first procedure in Austin. The system uses a non-permanent implant to remodel the obstructed prostatic urethra in patients with benign prostatic hyperplasia.
Why it matters
The technology aims to resolve lower urinary tract symptoms without the risks associated with permanent foreign material. Its arrival offers a new temporary procedural option for urology practices managing common prostate obstructions.
The Expander-2 trial tracked 240 patients across 23 sites, showing a 49% improvement in symptom scores at 12 months. The device is designed for a six-month implantation period before retrieval.
The players
Prodeon Medical
A medical device manufacturer focused on urological interventions for benign prostatic hyperplasia.
Tyler McClintock
The physician who performed the inaugural commercial procedure of the Urocross Expander System.
The Hospital at Westlake Medical Center
A medical facility in Austin, Texas, that served as the site for the first commercial deployment of the device.
The details
The Urocross system is inserted through a flexible cystoscope to physically open the prostatic urethra, providing a mechanical solution for obstruction. Because the device is temporary, the implant is retrieved after six months, distinguishing the approach from permanent stents or surgical tissue removal. Prodeon Medical is prioritizing physician training and clinical support as part of its initial controlled market entry.
Timeline
October 14, 2026: The first commercial procedure was performed in Austin.
Market Landscape
The launch marks a departure from the industry standard of permanent implants by offering a removable alternative. This approach shifts the competitive dynamic for practices currently relying on the permanent implant model established by systems like UroLift.
Operators in urology should assess how the six-month device retrieval requirement alters their current surgical scheduling and follow-up workflows. The shift toward non-permanent material may influence patient uptake, necessitating a review of practice protocols for long-term patient monitoring.
The takeaway
The introduction of temporary implants provides a new pathway for managing prostatic obstruction without the permanence of current surgical standards. Physicians and practice managers should track 12-month patient symptom outcomes to evaluate whether this temporary method fits their specific volume of benign prostatic hyperplasia cases.
Further reading
Explore more analysis of medical device adoption in our Healthcare section.
Live Poll
Would you prefer a removable medical implant over a permanent one for a chronic condition?
